Medivir AB Release: An All-Oral Combination Phase II Study of Simeprevir and Samatasvir (IDX719) for the Treatment of Hepatitis C Virus Infection Initiated

Published: May 30, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that Idenix Pharmaceuticals Inc. has initiated a phase II clinical trial, called HELIX-1, evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of simeprevir, a once-daily protease inhibitor jointly developed by Medivir and Janssen R&D Ireland and samatasvir (IDX719), Idenix’s once-daily pan-genotypic NS5A inhibitor.

Help employers find you! Check out all the jobs and post your resume.

Back to news